Home » Breast » MacroGenics stock falls after study shows breast-cancer survival rates for drug didn't surpass standard treatment - MarketWatch

By Loko Pondos Tuesday, September 7, 2021 Breast

MacroGenics stock falls after study shows breast-cancer survival rates for drug didn't surpass standard treatment - MarketWatch

Bagikan Berita Ini

0 Response to "MacroGenics stock falls after study shows breast-cancer survival rates for drug didn't surpass standard treatment - MarketWatch"

Post a Comment

Subscribe to: Post Comments (Atom)